Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ambenonium→

Ambenonium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
7648-98-8
Molecular formula
C28H42Cl2N4O2+2
Molecular weight
537.6 g/mol
Drug class
Reversible acetylcholinesterase inhibitorlong-acting quaternary ammonium cholinergic agent
Mechanism of action
Inhibits acetylcholinesterase, increasing acetylcholine concentrations at the neuromuscular junction and improving neuromuscular transmission. Its quaternary ammonium structure limits central nervous system penetration.
Indications / reported uses
  • Historically used for symptomatic treatment of myasthenia gravis; current availability and authorised status are limited and must be verified in the relevant jurisdiction

Sources: NLM MeSH — Ambenonium · PubMed — Ambenonium and myasthenia gravis clinical literature · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Reversible acetylcholinesterase inhibitor; long-acting quaternary ammonium cholinergic agent

Mechanism of action

Inhibits acetylcholinesterase, increasing acetylcholine concentrations at the neuromuscular junction and improving neuromuscular transmission. Its quaternary ammonium structure limits central nervous system penetration.

General use cases

  • Historically used for symptomatic treatment of myasthenia gravis; current availability and authorised status are limited and must be verified in the relevant jurisdiction

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Ambenonium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ambenonium Permitted Daily Exposure (PDE) report (the Ambenonium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ambenonium Occupational Exposure Limit (OEL) report (the Ambenonium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.